The firm said that it is delaying clinical trials prior to its FDA submission of Verigene 2 for several reasons, including reducing cassette failure rates.
The firm's life science segment grew revenues 8 percent, but revenues from its diagnostics segment saw revenues retreated 4 percent.
The fourth test for which the firm has received regulatory clearance this year takes aim at a common microbial cause of healthcare-associated infections.
PerkinElmer's subsidiary Wallac will now distribute the Amplidiag product line in Israel and in a number of countries in Africa.
The test can generate results in around 35 minutes from stool samples and requires no upfront nucleic acid extraction.
Analyses of Clostridium difficile isolates from hundreds of European hospitals led to clusters of apparent hospital-acquired cases and of infections with other potential sources.
The stool bank OpenBiome has a new storefront in Massachusetts, WGBH News reports.
The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.
The assay has been available outside the US since November and runs on the Liaison MDX benchtop instrument.
The firm said that it has completed clinical trials for the Group B Strep assay for the FDA and will start trials for the C. difficile test this month.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.